Page 1

bionano GENOMICS THE STRUCTURAL VARIATION COMPANY Lineagen A BIONANO GENOMICS Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress 226 % year - over - year total revenue increase driven by growth in the Saphyr installed base All 2021 milestones on track Strong balance sheet with $ 333 million in cash as of June 30 , 2021 Conference call today , Wednesday , August 4 , at 4:30 pm ET SAN DIEGO , August 4 , 2021 Bionano Genomics , Inc. ( NASDAQ : BNGO ) today reported financial results and business achievements for the second quarter ended June 30 , 2021 and highlighted recent corporate updates . — " We had a strong quarter to cap off the first half of 2021 , which we believe was one of the most transformational periods in Bionano's history . For the quarter ended June 30 , 2021 , total revenue was $ 3.9 million , up 226 % on a year - over - year basis , and we demonstrated great performance in many areas of our execution , including the achievement of our strategic goals to facilitate customer development of laboratory developed tests ( LDTs ) based on optical genome mapping ( OGM ) with Saphyr and to gain accreditation in certain European countries , " commented Erik Holmlin , PhD , CEO of Bionano Genomics . " With OGM , we are aiming to transform the way the world sees the genome in our relentless pursuit of enabling genomic insights and elevating human wellness . " Chris Stewart , Chief Financial Officer of Bionano added : " The second quarter of 2021 was very positive for Bionano , with steady and continued year - over - year revenue growth , a strong cash position of $ 333 million at quarter - end , and significant momentum in the cytogenetics market with increased global adoption of our product . To gain further traction in the market , we are focused on reimbursement in the United States , converting the existing cytogenetics workflow in Europe and increasing our installed base to our target number of 150 Saphyr systems by year - end . " Key Business Highlights The Company executed on its commercialization strategy , continued to build scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe , with the following highlights : Shipped 13 Saphyr systems in the quarter ended June 30 , 2021 , compared to 6 systems shipped in the same quarter in 2020. Installations completed in the